Agent Description
Atezolizumab is an Fc-engineered, humanized, monoclonal antibody that binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors. Atezolizumab is a non-glycosylated IgG1 kappa immunoglobulin that has a calculated molecular mass of 145 kDa.
Mechanism of Action
Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors. This releases the PD-L1/PD-1 mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.
Classification
PD-L1 inhibitor
Molecular Target
PD-L1
Monograph
Atezolizumab is approved in the U.S. with the trade name of TECENTRIQ® for the following indications:
- Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- have disease progression during or following platinum-containing chemotherapy
- have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy
- Metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Atezolizumab.
In addition to the two FDA approved indications above, atezolizumab is also being developed both as a monotherapy and in combination with standard treatments in a number of tumor types:
- Atezolizumab monotherapy: NSCLC, Urothelial Carcinoma (UC)
- Atezolizumab + chemotherapy: hematologic malignancies, triple negative breast cancer, urothelial carcinoma, NSCLC, SCLC
- Atezolizumab + radiotherapy: NSCLC, UC
- Atezolizumab + bevacizumab: renal cell carcinoma (RCC), urothelial carcinoma, colorectal cancer (CRC)
- Atezolizumab + cobimetinib: CRC, UC, melanoma (BRAF wild-type)
- Atezolizumab + ipilimumab: solid tumors
- Atezolizumab + interferon-alpha: solid tumors
- Atezolizumab + cobimetinib & vemurafenib: melanoma (BRAF-mutant), thyroid
- Atezolizumab + BCG: UC
- Atezolizumab + obinutuzumab: lymphomas
- Atezolizumab + erlotinib: NSCLC
- Atezolizumab + alectinib: NSCLC
View the atezolizumab package insert (PDF).
Studies of Interest
Areas of Interest
- tumor types not currently under study by the Pharmaceutical Company Collaborator
- novel combinations with standard treatments not currently under study by the Pharmaceutical Company Collaborator
- studies in relevant patient subpopulations
- correlative studies focused on relationships between immune biology and clinical response
- early stage studies, e.g., neoadjuvant setting, in tumors not currently under study
Areas NOT of Interest
- head-to-head studies with other PD-1/PD-L1 drugs
- studies of novel dosing and schedules of administration
- small under-powered randomized studies
Information collaborator would like included in investigator proposals
N/A